Article
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity…
bioRxiv: the preprint server for biology · 2021 · Penny L Moore, author Thandeka Moyo-Gwete, author Tandile Hermanus, author Prudence Kgagudi, author Frances Ayres, author Zanele Makhado, author Jerald Sadoff, author Mathieu Le Gars, author Griet van Roey, author Carol Crowther, author Nigel Garrett, author Linda-Gail Bekker, author Lynn Morris, author Hanneke Schuitemaker, author Glenda Gray, author
Key facts
| Title | Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant |
|---|---|
| First author | Penny L Moore, author Thandeka Moyo-Gwete, author Tandile Hermanus, author Prudence Kgagudi, author Frances Ayres, author Zanele Makhado, author Jerald Sadoff, author Mathieu Le Gars, author Griet van Roey, author Carol Crowther, author Nigel Garrett, author Linda-Gail Bekker, author Lynn Morris, author Hanneke Schuitemaker, author Glenda Gray, author |
| Journal | bioRxiv : the preprint server for biology |
| Published | Jun 12, 2021 |
| DOI | 10.1101/2021.06.09.447722 |
| Devices mentioned | K822496 |
| Product codes mentioned | JIT |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1